Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Introduction Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is a progressive disease resulting from the accumulation of wild-type transthyretin (TTR) amyloid fibrils, and is diagnosed primarily in males. This analysis examined sex differences in patients with ATTRwt amyloidosis from the Tr...

Full description

Saved in:
Bibliographic Details
Published in:Cardiology and Therapy 2022-09, Vol.11 (3), p.393-405
Main Authors: Campbell, Courtney M., LoRusso, Samantha, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Rapezzi, Claudio, Lairez, Olivier, Drachman, Brian, Garcia-Pavia, Pablo, Grogan, Martha, Chapman, Doug, Amass, Leslie
Format: Article
Language:English
Subjects:
Amyloidosis
Cardiology
Care and treatment
Diagnosis
Genetic aspects
Internal Medicine
Medicine
Medicine & Public Health
NCT
NCT00628745
Original Research
Patient outcomes
Pharmaceutical industry
Surveys
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is a progressive disease resulting from the accumulation of wild-type transthyretin (TTR) amyloid fibrils, and is diagnosed primarily in males. This analysis examined sex differences in patients with ATTRwt amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Methods THAOS is an ongoing, global, longitudinal, observational survey of patients with transthyretin amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of TTR mutations. THAOS data were analyzed to identify potential differences in demographic and clinical characteristics between males and females with ATTRwt amyloidosis (data cutoff: August 1, 2021). Results Of 1386 patients with ATTRwt amyloidosis, 84 (6%) were female and 1302 (94%) were male. Females had a higher median age at enrollment (80 vs. 78 years; p  = 0.002) and symptom onset (75 vs. 73 years; p  = 0.045) than males. Mean left ventricular (LV) ejection fraction was higher (53% vs. 48%; p  = 0.001) and mean LV diastolic diameter lower (42 vs. 46 mm; p  
ISSN:2193-8261
2193-6544
DOI:10.1007/s40119-022-00265-7